Patents by Inventor Federico Bertoglio

Federico Bertoglio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC ANTIBODIES WITH NEUTRALIZING ACTIVITY AGAINST SARS-COV-2 GLYCOPROTEIN S
    Publication number: 20240059758
    Abstract: The present invention is related to antibodies and antigen-binding fragments of antibodies that specifically bind the SARS-CoV-2 glycoprotein S (spike) as well as diagnostic and therapeutic methods of using those antibodies.
    Type: Application
    Filed: May 19, 2021
    Publication date: February 22, 2024
    Inventors: André Frenzel, Philipp Kuhn, Jonas Kügler, Michael Hust, Stefan Dübel, Doris Meier, Federico Bertoglio, Maren Schubert, Stephan Steinke, Marlies Becker, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Kai-Thomas Schneider, Rico Ballmann, Susanne Zock-Emmenthal, Kristian Daniel Ralph Roth, Nora Langreder
  • Compositions and use of a fibrinogen binding motif present in EFB and COA for therapeutics and vaccines against
    Patent number: 11407819
    Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: August 9, 2022
    Assignees: The Texas A&M University System, Technische Universität Braunschweig, Università Degli Studi Di Pavia
    Inventors: Ya-Ping Ko, Magnus Hook, Srishtee Arora, Livia Visai, Federico Bertoglio, Michael Hust, Doris Meier
  • THREE-DIMENSIONAL SUBSTRATE FOR MICROBIAL CULTURES
    Publication number: 20220073857
    Abstract: A three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures is provided. The three-dimensional substrate includes a diffusion system having a first apical compartment placed above a second basolateral compartment, the first and second compartments being separated by a semipermeable membrane, a base solution comprising polysaccharides, proteins and salts or a preformed hydrogel comprising polysaccharides, proteins and salts, and a cross-linking medium comprising salts, culture media and distilled water. A method for preparing a three-dimensional substrate with structural and compositional gradient for microbial cultures and cocultures is also provided.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 10, 2022
    Inventors: Paola PETRINI, Daniela Patricia PENEDA PACHECO, Natalia Andrea SUAREZ VARGAS, Federico BERTOGLIO, Sonja VISENTIN, Livia VISAI
  • COMPOSITIONS AND USE OF A FIBRINOGEN BINDING MOTIF PRESENT IN EFB AND COA FOR THERAPEUTICS AND VACCINES AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20200283508
    Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.
    Type: Application
    Filed: May 20, 2020
    Publication date: September 10, 2020
    Inventors: Ya-Ping Ko, Magnus Hook, Suzan HM Rooijakkers, Livia Visai, Federico Bertoglio, Michael Hust, Doris Meier